Yu Liu1, Linli Liu1, Fang Yan1. 1. Department of Cardiac Surgery, The Second Hospital of Hebei Medical University Shijiiazhuang 050000, Hebei, China.
Abstract
BACKGROUND: Previous studies have shown that levosimendan can reduce mortality and complications in patients undergoing cardiac surgery. The purpose of this study was to investigate the effect of levosimendan on the recovery of cardiac function, quality of life and prognosis in patients with heart disease after operation. METHODS: From October 2017 to August 2019, 93 patients admitted to our hospital for cardiac surgery were retrospectively enrolled in this study. Fifty-three patients treated with levosimendan were included in the experimental group (EG) and 40 who did not receive levosimendan were recruited into the control group (CG). After operation, the length of ICU stay and hospitalization, mean arterial pressure, central venous pressure, heart rate, the changes of cardiac parameters (left ventricular end diastolic volume (LVEDV), end-systolic volume (LVESV), left ventricular ejection index (LVEF) and cardiac index (CI) at different time points), and the changes of high sensitive troponin I (hs-cTnI), creatine kinase isoenzyme (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were compared between the two groups. The stroke volume index (SVI), left ventricular stroke work index (LVSWI), systemic vascular resistance index (SVRI) and other hemodynamic indexes were also compared. RESULTS: The length of ICU stay and hospitalization time in the EG were shorter than those in the CG. After treatment, MAP (mean arterial pressure), CVP (central venous pressure), HR (heart rate), LVEDV, LVESV, HS CTN, NT proBNP and SVRI in the EG were lower than those in the CG group, while LVEF, CI, SVI and LVSWI were higher than those in the CG. The quality of life of patients in the EG was better than that of those in the CG one month after treatment. Logistics regression analysis revealed that the use of levosimendan can reduce the risk of death. CONCLUSION: Levosimendan can improve the cardiac function and prognosis of patients after cardiac surgery, which is worthy of clinical promotion. AJTR
BACKGROUND: Previous studies have shown that levosimendan can reduce mortality and complications in patients undergoing cardiac surgery. The purpose of this study was to investigate the effect of levosimendan on the recovery of cardiac function, quality of life and prognosis in patients with heart disease after operation. METHODS: From October 2017 to August 2019, 93 patients admitted to our hospital for cardiac surgery were retrospectively enrolled in this study. Fifty-three patients treated with levosimendan were included in the experimental group (EG) and 40 who did not receive levosimendan were recruited into the control group (CG). After operation, the length of ICU stay and hospitalization, mean arterial pressure, central venous pressure, heart rate, the changes of cardiac parameters (left ventricular end diastolic volume (LVEDV), end-systolic volume (LVESV), left ventricular ejection index (LVEF) and cardiac index (CI) at different time points), and the changes of high sensitive troponin I (hs-cTnI), creatine kinase isoenzyme (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were compared between the two groups. The stroke volume index (SVI), left ventricular stroke work index (LVSWI), systemic vascular resistance index (SVRI) and other hemodynamic indexes were also compared. RESULTS: The length of ICU stay and hospitalization time in the EG were shorter than those in the CG. After treatment, MAP (mean arterial pressure), CVP (central venous pressure), HR (heart rate), LVEDV, LVESV, HS CTN, NT proBNP and SVRI in the EG were lower than those in the CG group, while LVEF, CI, SVI and LVSWI were higher than those in the CG. The quality of life of patients in the EG was better than that of those in the CG one month after treatment. Logistics regression analysis revealed that the use of levosimendan can reduce the risk of death. CONCLUSION: Levosimendan can improve the cardiac function and prognosis of patients after cardiac surgery, which is worthy of clinical promotion. AJTR
Authors: David B Antcliffe; Shalini Santhakumaran; Robert M L Orme; Josie K Ward; Farah Al-Beidh; Kieran O'Dea; Gavin D Perkins; Mervyn Singer; Daniel F McAuley; Alexina J Mason; Mary Cross; Deborah Ashby; Anthony C Gordon Journal: Intensive Care Med Date: 2019-08-19 Impact factor: 17.440
Authors: Giovanni Landoni; Vladimir V Lomivorotov; Gabriele Alvaro; Rosetta Lobreglio; Antonio Pisano; Fabio Guarracino; Maria G Calabrò; Evgeny V Grigoryev; Valery V Likhvantsev; Marcello F Salgado-Filho; Alessandro Bianchi; Vadim V Pasyuga; Massimo Baiocchi; Federico Pappalardo; Fabrizio Monaco; Vladimir A Boboshko; Marat N Abubakirov; Bruno Amantea; Rosalba Lembo; Luca Brazzi; Luigi Verniero; Pietro Bertini; Anna M Scandroglio; Tiziana Bove; Alessandro Belletti; Maria G Michienzi; Dmitriy L Shukevich; Tatiana S Zabelina; Rinaldo Bellomo; Alberto Zangrillo Journal: N Engl J Med Date: 2017-03-21 Impact factor: 91.245
Authors: Paulo Ernando Ferraz Cavalcanti; Michel Pompeu Barros de Oliveira Sá; Cecília Andrade dos Santos; Isaac Melo Esmeraldo; Mariana Leal Chaves; Ricardo Felipe de Albuquerque Lins; Ricardo de Carvalho Lima Journal: Rev Bras Cir Cardiovasc Date: 2015 Mar-Apr
Authors: Lisanne Roesthuis; Hans van der Hoeven; Christer Sinderby; Tim Frenzel; Coen Ottenheijm; Laurent Brochard; Jonne Doorduin; Leo Heunks Journal: Intensive Care Med Date: 2019-10-01 Impact factor: 17.440